Although the relationship between PXR and aberrant TLR-mediated immune responses in PBC is far from being completely understood, PXR has been proposed as a novel therapeutic target for diseases characterized by excessive TLR4 activation, such as intestinal inflammatory disorders, since PXR negatively regulates TLR4 [53]. Here, NR1I2 is linked to primary biliary cholangitis.